Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: A prospective observational study

V. Belcastro, C. Costa, F. Galletti, F. Pisani, P. Calabresi, L. Parnetti

Research output: Contribution to journalArticle

Abstract

Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study. At a daily dose of 1000-1500 mg, 72% were seizure-free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow-up. These results suggest the need for controlled studies to confirm if LEV can be a first-choice drug in AD.

Original languageEnglish
Pages (from-to)1176-1178
Number of pages3
JournalEuropean Journal of Neurology
Volume14
Issue number10
DOIs
Publication statusPublished - Oct 2007

Keywords

  • Alzheimer's disease
  • Antiepileptic drugs
  • Dementia
  • Late-onset seizures
  • Levetiracetam

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: A prospective observational study'. Together they form a unique fingerprint.

  • Cite this